More data on the long-term effects of Racemic Ketamine and Esketamine in TDR patients is needed. The implementation of centralized registries of their use for treatment of depression could be a tool of major importance for assessing their efficacy and safety in real-world clinical practice. This paper seeks to outline the rise and rationale behind these registry-based surveillance systems.
Keywords: Depression; Esketamine; Ketamine; Treatment-resistant depression.
Copyright © 2021 Elsevier B.V. All rights reserved.